|
CSTF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.37942998637664E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.30975263757227E-12 |
| Normal-vs-Stage2 |
9.154500E-04 |
| Normal-vs-Stage3 |
1.31580002449283E-09 |
| Normal-vs-Stage4 |
6.70660194046491E-11 |
| Stage1-vs-Stage2 |
1.904960E-01 |
| Stage1-vs-Stage3 |
9.933000E-01 |
| Stage1-vs-Stage4 |
2.821600E-02 |
| Stage2-vs-Stage3 |
2.156000E-01 |
| Stage2-vs-Stage4 |
9.795700E-03 |
| Stage3-vs-Stage4 |
4.087600E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.66955338443131E-12 |
| Normal-vs-AfricanAmerican |
3.764000E-04 |
| Normal-vs-Asian |
4.42529999999941E-06 |
| Caucasian-vs-AfricanAmerican |
5.724400E-01 |
| Caucasian-vs-Asian |
5.146400E-01 |
| AfricanAmerican-vs-Asian |
9.477200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.20369996987102E-09 |
| Normal-vs-Female |
2.61701771364642E-12 |
| Male-vs-Female |
6.824600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.81079595762412E-11 |
| Normal-vs-Age(41-60Yrs) |
2.30079999496979E-09 |
| Normal-vs-Age(61-80Yrs) |
6.30620000663384E-09 |
| Normal-vs-Age(81-100Yrs) |
6.463000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.930200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.343600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.974600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.810200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.360200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.362600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.134300E-02 |
| Classical-VS-Follicular |
2.710000E-01 |
| Classical-VS-Other |
1.895020E-01 |
| Classical-VS-Normal |
4.70810057606741E-11 |
| Tall-VS-Follicular |
2.670800E-01 |
| Tall-VS-Other |
8.454600E-01 |
| Tall-VS-Normal |
2.20370000025838E-09 |
| Follicular-VS-Other |
5.033400E-01 |
| Follicular-VS-Normal |
8.11400000522156E-08 |
| Other-VS-Normal |
1.975240E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.29300001208799E-09 |
| Normal-vs-N1 |
7.06323888266525E-12 |
| N0-vs-N1 |
2.081200E-03 |
|
|
